You are using an older version of Internet Explorer that is not supported on this site. Please upgrade for the best experience.

A Double-blind, Randomised, Placebo-controlled, Phase 2b/3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients with Vasopressor-dependent Septic Shock

793725
Infection
Mark Tidswell, MD

Baystate Medical Center

759 Chestnut Street

Springfield, MA  01199

The purpose of this study is to investigate the efficacy and safety of multiple dosing regimens of selepressin and to confirm the efficacy and safety of one dosing regimen in treatment of adult patients with septic shock requiring vasopressor.

Eligible participants must be at least 18 years of age with proven or suspected infection as well as septic shock.
Lori-Ann Kozikowski
413-794-5584